Emerging pharmacotherapies for androgenetic alopecia.
Confirms ABS-201 is in clinical development for androgenetic alopecia as a prolactin-receptor-targeting biologic. It contains no data on whether it works.
Where it sits
this study against the rest of the abs-201 corpusSummary and findings
A narrative review of emerging drug development for androgenetic alopecia. It lists ABS-201 alongside HMI-115 as biologics targeting prolactin receptor inhibition, within a wider survey of investigational approaches. It reports no efficacy or safety data specific to ABS-201.
Abstract
<h4>Introduction</h4>Androgenetic alopecia (AGA) is the most common form of hair loss, characterized by androgen-dependent follicular miniaturization. To date, topical and oral minoxidil, 5-α-reductase inhibitors and oral antiandrogens remain the mainstay of treatment, but research is progressing fast in the search of new mechanism-targeted pharmacotherapies.<h4>Areas covered</h4>This article summarizes emerging therapies for AGA and highlights their underlying mechanisms. A targeted review was conducted of PubMed, ClinicalTrials.gov, Food and Drug Administration available resources, company-press releases and published abstracts from database inception through December 2025.<h4>Expert opinion</h4>Recent advances in hair biology and drug development have led to a paradigm shift toward new strategies to prevent androgen effects on the follicle, improve minoxidil delivery, activate follicle stem cells and prevent follicular apoptosis. These include topical androgen-receptor antagonists and degraders (clascoterone, GT20029), biologics targeting prolactin receptor inhibition (HMI-115, ABS-201), anagen-inducing injectables (AMP-303), metabolic and follicular activators (PP405, ET-02), thyroid hormone receptor-β agonists (KB-141), optimized potassium channel opener delivery systems (extended-release and sublingual minoxidil) and modulation of longevity pathways using rapamycin and metformin. Collectively, these newer pharmacotherapeutics aim to improve efficacy, safety, and patient adherence. Ongoing and future clinical trials will determine their definitive role in reshaping the therapeutic landscape of androgenetic alopecia.
Key findings
- Lists ABS-201 among biologics targeting prolactin receptor inhibition for androgenetic alopecia.
- Surveys the emerging androgenetic alopecia pipeline broadly rather than reporting outcomes for any single agent.
- Reports no efficacy or safety data for ABS-201.
Limitations
A narrative review rather than a study of ABS-201. Its mention of the compound describes development status and does not report any measured outcome, so it establishes that the compound exists and is in development, and nothing more.